DK3395423T3 - Fjernelse af lækket affinitetsoprensningsligand - Google Patents

Fjernelse af lækket affinitetsoprensningsligand Download PDF

Info

Publication number
DK3395423T3
DK3395423T3 DK18168494.5T DK18168494T DK3395423T3 DK 3395423 T3 DK3395423 T3 DK 3395423T3 DK 18168494 T DK18168494 T DK 18168494T DK 3395423 T3 DK3395423 T3 DK 3395423T3
Authority
DK
Denmark
Prior art keywords
leaked
removal
affinity purification
purification ligand
ligand
Prior art date
Application number
DK18168494.5T
Other languages
Danish (da)
English (en)
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3395423(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK3395423T3 publication Critical patent/DK3395423T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18168494.5T 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand DK3395423T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
EP14714890.2A EP2969099B2 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (1)

Publication Number Publication Date
DK3395423T3 true DK3395423T3 (da) 2023-11-20

Family

ID=50424772

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18168494.5T DK3395423T3 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand
DK14714890.2T DK2969099T4 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14714890.2T DK2969099T4 (da) 2013-03-14 2014-03-11 Fjernelse af lækket affinitetsoprensningsligand

Country Status (17)

Country Link
US (3) US20160024144A1 (cg-RX-API-DMAC7.html)
EP (3) EP4026596A1 (cg-RX-API-DMAC7.html)
JP (1) JP6457479B2 (cg-RX-API-DMAC7.html)
AU (1) AU2014240596B2 (cg-RX-API-DMAC7.html)
CA (1) CA2904411A1 (cg-RX-API-DMAC7.html)
CY (1) CY1120353T1 (cg-RX-API-DMAC7.html)
DK (2) DK3395423T3 (cg-RX-API-DMAC7.html)
ES (2) ES2964601T3 (cg-RX-API-DMAC7.html)
FI (1) FI3395423T3 (cg-RX-API-DMAC7.html)
HU (2) HUE038565T2 (cg-RX-API-DMAC7.html)
LT (2) LT2969099T (cg-RX-API-DMAC7.html)
MX (2) MX365501B (cg-RX-API-DMAC7.html)
PL (2) PL2969099T5 (cg-RX-API-DMAC7.html)
PT (2) PT2969099T (cg-RX-API-DMAC7.html)
SI (2) SI3395423T1 (cg-RX-API-DMAC7.html)
TR (1) TR201809050T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014159441A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160024144A1 (en) 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US10556942B2 (en) * 2014-06-13 2020-02-11 Lupin Limited Process for the purification of TNFR:Fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
JP7065105B2 (ja) * 2017-02-09 2022-05-11 ブラッコ・スイス・ソシエテ・アノニム 可溶性ｐｓｇｌ－１タンパク質変異体の精製のための方法
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
ATE204004T1 (de) 1996-06-21 2001-08-15 Merck Patent Gmbh Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6398962B1 (en) 1997-06-18 2002-06-04 Merck Kgaa Use of monolithic sorbents for preparative chromatographic separation
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
EP1463942B2 (en) 2001-12-21 2012-06-20 Immunex Corporation Methods for purifying protein
CN104610422A (zh) * 2005-03-11 2015-05-13 惠氏公司 弱分配层析的方法
TW200827445A (en) * 2006-11-08 2008-07-01 Wyeth Corp Rationally designed media for cell culture
BRPI1009447A2 (pt) * 2009-03-11 2016-03-01 Wyeth Llc métodos de purificação de proteínas imunofarmacêuticas modulares pequenas
EP2598515B1 (en) * 2010-07-30 2016-09-21 Pfizer Inc Tandem purification of proteins
EP2723759A4 (en) * 2011-06-24 2015-01-28 Reddys Lab Ltd Dr PURIFICATION OF CHIMERIC PROTEIN
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
WO2013063702A1 (en) * 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
US20160024144A1 (en) * 2013-03-14 2016-01-28 Amgen Inc. Removal of leaked affinity purification ligand

Also Published As

Publication number Publication date
US20220144886A1 (en) 2022-05-12
CA2904411A1 (en) 2014-10-02
EP2969099B1 (en) 2018-04-25
PL2969099T3 (pl) 2018-10-31
ES2674697T3 (es) 2018-07-03
HUE064450T2 (hu) 2024-03-28
MX365501B (es) 2019-06-05
AU2014240596B2 (en) 2018-09-27
US11192919B2 (en) 2021-12-07
EP4026596A1 (en) 2022-07-13
HUE038565T2 (hu) 2018-10-29
MX2019006568A (es) 2019-08-22
US11492372B2 (en) 2022-11-08
EP3395423A1 (en) 2018-10-31
EP2969099B2 (en) 2021-12-22
AU2014240596A1 (en) 2015-09-24
PT3395423T (pt) 2023-11-14
FI3395423T3 (fi) 2023-11-02
CY1120353T1 (el) 2019-07-10
DK2969099T3 (en) 2018-07-09
JP2016513643A (ja) 2016-05-16
PL3395423T3 (pl) 2024-03-18
TR201809050T4 (tr) 2018-07-23
EP2969099A1 (en) 2016-01-20
DK2969099T4 (da) 2022-03-14
MX391507B (es) 2025-03-21
SI2969099T2 (sl) 2022-04-29
HK1220159A1 (en) 2017-04-28
ES2964601T3 (es) 2024-04-08
JP6457479B2 (ja) 2019-01-23
MX2015011994A (es) 2015-12-01
SI3395423T1 (sl) 2023-12-29
PT2969099T (pt) 2018-07-05
US20160024144A1 (en) 2016-01-28
SI2969099T1 (sl) 2018-09-28
ES2674697T5 (es) 2022-04-19
WO2014159441A1 (en) 2014-10-02
US20190085021A1 (en) 2019-03-21
PL2969099T5 (pl) 2022-06-13
LT3395423T (lt) 2023-12-11
LT2969099T (lt) 2018-09-10
EP3395423B1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
FIC20240024I1 (fi) Lutetium (177Lu) vipivotiditetraksetaani
DK2970954T3 (da) Modifikation af polypeptider
DK2968208T3 (da) Behandling af kataplexi
BR112015019232A2 (pt) filtração
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3043827T3 (da) Modulatorer af komplement faktor b
DK3068854T3 (da) Fjernelse af uønskede propanolkomponenter
DK2961388T3 (da) Kombinationer af lægemidler
DK3680000T3 (da) Fremgangsmåder til oprensning af antistoffer
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
EP2982134A4 (en) AUDIO FILTER WITH SINUS FUNCTIONS
DK2991543T3 (da) System til visualisering af kropsområder
DK3063264T3 (da) Tørring af mikroorganismer
DK2969099T4 (da) Fjernelse af lækket affinitetsoprensningsligand
EP2948557A4 (en) CLEANING OF CADAVERIN
DK2822301T3 (da) Bestemmelse af individuelle HRTF
DE112014001869A5 (de) Bearbeitungszentrum
DK2838850T3 (da) Oprensning af titantetrachlorid
PL2765250T3 (pl) Rynna odpływowa
DK3080574T3 (da) Overvågning af ringvolumen
TH1301002962B (th) ตัวดูดซับสำหรับการกำจัดคลอไรด์
TH1501000312A (th) ตัวกรอง
UA25836S (uk) Фільтр масляний
UA25702S (uk) Фільтр масляний
UA25368S (uk) Фільтр масляний